Ask VialBase
review · PMID 16300975

Growth hormone-releasing hormone analogs: chemistry and pharmacology — VialBase Research

high

Last updated · 2006 · Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J.P., Stoch, S.A., Bhatt, R.S. · Growth Hormone & IGF Research
Key findings
  • Reviews GHRH analog development including CJC-1295
  • DAC technology extends GHRH analog half-life via albumin binding
  • CJC-1295 maintains pulsatile GH release pattern unlike exogenous GH

⚠️ [PMID unverified — flagged 2026-06-19] — PMID 16300975 resolves to an unrelated paper (NCBI: a CRPS/ISS impairment study), not the Alba/Fintini “GHRH analogs: chemistry and pharmacology” review. The correct record (candidate: 16822960, Alba/Fintini CJC-1295 GHRH-KO mouse 2006) was not confidently confirmed for this note. Treat this PMID as unverified.

Summary

Review of GHRH analog chemistry and pharmacology, with focus on modifications that improve stability and extend half-life. Covers the development of CJC-1295 and the Drug Affinity Complex (DAC) technology that enables once-weekly dosing through reversible albumin binding.

Key Findings

  • GHRH analogs like CJC-1295 stimulate GH release while preserving natural pulsatility
  • DAC (Drug Affinity Complex) modification enables covalent albumin binding, extending half-life
  • Pulsatile GH release pattern maintained — unlike flat exogenous GH administration
  • CJC-1295 stimulates GH at the pituitary level, preserving negative feedback loops
  • Modified amino acid sequence improves resistance to DPP-IV degradation
  • Represents an alternative to exogenous GH replacement with potentially better safety profile

Methodology

Narrative review covering GHRH peptide chemistry, structure-activity relationships, pharmacokinetic modifications, and clinical pharmacology data for various GHRH analogs including CJC-1295.

Limitations

  • Review focused on pharmacology — limited clinical outcome data
  • DAC technology is specific to the DAC formulation (not “no-DAC” versions)
  • Long-term safety of sustained GH/IGF-1 elevation not addressed
  • Theoretical advantages over exogenous GH not validated in comparative trials
  • Commercial development was discontinued after adverse events in clinical trials

Relevance to Content

Essential for content explaining why CJC-1295 is preferred over exogenous GH in the peptide space. The “preserving pulsatility” argument is a key differentiator. Also important context: the commercial (DAC) version had clinical trial adverse events — content should note the distinction between clinical-grade DAC and “no-DAC” versions used in practice.

See Also

View on PubMed · PMID 16300975 →